A therapeutic and side effects comparison between domestic type and the similar brand in gastric cancer.

A therapeutic and side effects comparison between Rosastim and Brand type (Neupogen) in gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014061118061N1

Enrollment

Registered

2014-10-20

Start date

2013-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gasteric cancer. Malignant neoplasm of stomach

Interventions

Intervention 1: Neupogen prefilled syringe 300 microgram per 0.5 mL is as a control group, duration of treatment for each patient is about six months. blood sampling is done consecutive days, then one

Treatment - Drugs

Neupogen prefilled syringe 300 microgram per 0.5 mL is as a control group, duration of treatment for each patient is about six months. blood sampling is done consecutive days, then one day is rest, af

Rosastim 300ug/0.5mL is a subcutaneous prefilled syringe. duration of treatment for each patient is about six months. blood sampling is done consecutive days, then one day is rest, after that sampling

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 1.Patients with gastric cancers, age 18-65, both sex 2.Biopsy and pathology results 3.Filling the consent form through patients or guardian 4.Possible cooperation of patients till the study completed. exclusion criteria: 1.Ill-informed patient consent for participation in the study 2.Initial CBC disruption, so that lead to the wrong result in lab tests 3.Hypersensitivity to one type of Granolocyte Colony Stimulating Factor 4.History of treated malignancy or co-current malignancy 5.patient may require radiation during treatment 6.recurrent gastric cancer or refractory one that have previously been treated 7.Inappropriate performance status for start or continue treatment 8.Mental illness or depression such that the compliance reduce.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
White Blood Cell / Platlet / Hemoglubin measurement. Timepoint: triweekly. Method of measurement: Blood sample and Cell Blood Count measurement.	—

Secondary

Measure	Time frame
CRAMP OF LOWER LIMB , Balance cerebellar. Timepoint: triweekly. Method of measurement: Check up.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Babak Salimi

Taleghani Hospital

babak_salmd@yahoo.com+98 21224325609

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026